drug discovery

May 5, 2016

Current cancer drug discovery method flawed: VUMC study

The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers reported May 2 in Nature Methods.

By Leigh MacMillan
March 21, 2016

Putting schizophrenia to bed

A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation.

By VUMC News and Communications
December 10, 2015

Vanderbilt, Ono Pharmaceutical sign drug discovery agreement

Vanderbilt University Medical Center and Ono Pharmaceutical Group, an international company based in Japan, have signed a drug discovery agreement.

By Paul Govern
aspergillus culture
October 7, 2015

Rational design of novel antifungals

Structural and molecular details of an anti-fungal target’s interaction with inhibitors suggest ways to design better treatments for fungal infections.

By VUMC News and Communications
October 1, 2015

Collaboration seeks to develop new therapies for bone, other diseases

La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.

By Leigh MacMillan
July 15, 2015

Drug signaling networks

Vanderbilt investigators have developed a new algorithm to understand the networks of signaling molecules that control drug action.

By Leigh MacMillan
June 12, 2015

New strategy to combat HIV

Inhibitors of the enzyme phospholipase D1 suppress the replication of HIV-1, Vanderbilt investigators have discovered.
By Bill Snyder
February 12, 2015

Grant spurs schizophrenia research

Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness.
By Bill Snyder
February 10, 2015

Targeting HIV’s “cap”

New findings underscore the attractiveness of the HIV capsid – the structure that encloses the viral genome – as a therapeutic target.
By VUMC News and Communications
November 20, 2014

Receptor discovery shines new light on appetite regulation

A receptor in the brain that regulates appetite and body weight has now been found in L cells, key regulatory cells in the gut, providing the pharmaceutical industry with a novel drug target for both obesity and diabetes, a Vanderbilt University-led research team reported this week.
By Bill Snyder
September 4, 2014

Lung cancer study reveals new drug combination targets

A Vanderbilt lung cancer patient’s exceptional response to different types of therapies spurred research that suggests lung cancer patients with specific gene alterations may benefit from combination therapy that targets two different cancer pathways.
By VUMC News and Communications
August 20, 2014

Enzyme holds the door for influenza

Compounds developed at Vanderbilt University may offer a new way to block influenza infection.
By VUMC News and Communications
August 14, 2014

Growth factor blockade targets breast tumors

Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis.
By VUMC News and Communications
1 2 3